Superworth

Royalty Pharma forward PE RPRX

Share price divided by analysts' consensus earnings for the next twelve months, since 2020.

Today, Nov 3, 2026
13.6×
6-year median
9.3×
Against its 6-year history
81st
percentile: 0 is its lowest day, 100 its highest
6-year range
6.2× to 19.4×
Peer median
20.9×

Royalty Pharma's forward PE is 13.6× as of Nov 3, 2026.

That is above its 6-year median of 9.3×, higher than on 81% of days in the last 6 years.

Over that time it ranged from 6.2× in Dec 2024 to 19.4× in Jun 2020.

The median for 10 healthcare stocks of a similar size is 20.9×.

Forward PE over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far13.4×7.8×13.6×
20257.9×6.4×8.2×
20246.3×6.2×7.9×
20237.2×6.8×9.7×
20229.1×9.1×13.4×
202113.3×11.9×18.8×
202018.1×14.3×19.4×

Against its peers

Companies in Healthcare nearest Royalty Pharma's size, closest first, today.

CompanyForward PE
RPRXRoyalty Pharma13.6×
BIIBBiogen19.0×
GEHCGE HealthCare Technologies15.4×
ONCBeOne Medicines45.0×
IQVIQVIA19.0×
ZTSZoetis13.4×
ILMNIllumina41.5×
MTDMettler-Toledo International34.6×
RMDResMed18.4×
WATWaters30.4×
MDLNMedline22.7×
Peer median20.9×

Where Royalty Pharma ranks

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on Royalty Pharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.